This company has been marked as potentially delisted and may not be actively trading. NASDAQ:NYMX Nymox Pharmaceutical (NYMX) Stock Price, News & Analysis Add Compare Share Share Stock Analysis Stock AnalysisBuy This Stock About Nymox Pharmaceutical Stock (NASDAQ:NYMX) 30 days 90 days 365 days Advanced Chart Get Nymox Pharmaceutical alerts:Sign Up Key Stats Today's Range N/A50-Day Range$0.19▼$0.4752-Week Range N/AVolume932,700 shsAverage Volume94,622 shsMarket Capitalization$18.10 millionP/E RatioN/ADividend YieldN/APrice TargetN/AConsensus RatingN/A Company Overview Nymox Pharmaceutical Corporation, a biopharmaceutical company, engages in the research and development of drugs for the aging population in Canada, the United States, Europe, and internationally. Its lead drug candidate is Fexapotide Triflutate (NX-1207), which is in various clinical trials for the treatment of benign prostatic hyperplasia and low grade localized prostate cancer, as well as is in preclinical studies for hepatocellular carcinoma. The company also develops and markets NicAlert for detecting tobacco product usage; and TobacAlert for detecting second-hand smoke exposure. In addition, it develops drugs for the treatment of Alzheimer's disease. Nymox Pharmaceutical Corporation was founded in 1989 and is headquartered in Nassau, the Bahamas. Read More Receive NYMX Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Nymox Pharmaceutical and its competitors with MarketBeat's FREE daily newsletter. Email Address NYMX Stock News HeadlinesNymox Announces Filing of Annual ReportAugust 31, 2024 | markets.businessinsider.comNymox Annual ReportJuly 20, 2024 | finance.yahoo.comI was wrong about TrumpI made a mistake. A mistake I feel very foolish about. After speaking with Donald Trump and some of his advisors, I believed him. I believed the promise that he would finally confront the single most dangerous threat to American life. That he would fix the ticking time bomb I’ve been warning about for 15 years. But I was wrong.July 15 at 2:00 AM | Porter & Company (Ad)Nymox December 27 Message to ShareholdersDecember 27, 2023 | markets.businessinsider.comNymox Pharmaceutical Corporation: Nymox December 27 Message to ShareholdersDecember 27, 2023 | finanznachrichten.deNymox Reports California Court Issues Preliminary Injunction Against Defendants Lanham, Riley, Cutler and OthersNovember 30, 2023 | finance.yahoo.comNymox Pharmaceutical Corporation: $250 Million Lawsuit Filed Against AscellaHealth by Nymox Accepted and Summons Issued in California CourtNovember 22, 2023 | finanznachrichten.de$250 Million Lawsuit Filed Against AscellaHealth by Nymox Accepted and Summons Issued in California CourtNovember 21, 2023 | markets.businessinsider.comSee More Headlines NYMX Stock Analysis - Frequently Asked Questions How were Nymox Pharmaceutical's earnings last quarter? Nymox Pharmaceutical Co. (NASDAQ:NYMX) announced its quarterly earnings data on Friday, November, 14th. The biopharmaceutical company reported ($0.02) earnings per share for the quarter. The biopharmaceutical company earned $0.08 million during the quarter. What other stocks do shareholders of Nymox Pharmaceutical own? Based on aggregate information from My MarketBeat watchlists, some other companies that Nymox Pharmaceutical investors own include Quantum (QTM), Rocket Pharmaceuticals (RCKT), Idera Pharmaceuticals (IDRA), MEI Pharma (MEIP), Biocept (BIOC), TherapeuticsMD (TXMD) and CTI BioPharma (CTIC). Company Calendar Last Earnings11/14/2014Today7/15/2025Fiscal Year End12/31/2025Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Diagnostic substances Sub-IndustryN/A Current SymbolNASDAQ:NYMX CIK1018735 Webwww.nymox.com Phone(800) 936-9669Fax514-332-2227Employees3Year FoundedN/AProfitability EPS (Trailing Twelve Months)($0.04) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income-$6.58 million Net MarginsN/A Pretax MarginN/A Return on Equity-1,589.50% Return on Assets-117.25% Debt Debt-to-Equity RatioN/A Current Ratio0.19 Quick Ratio0.19 Sales & Book Value Annual SalesN/A Price / SalesN/A Cash FlowN/A Price / Cash FlowN/A Book Value($0.01) per share Price / BookN/AMiscellaneous Outstanding Shares90,510,000Free Float41,637,000Market Cap$18.10 million OptionableOptionable Beta0.64 Options Trading Made Easy - Download NowLearn the basics of options trading and how to use them to boost returns and manage risk with this free report from MarketBeat. Click the link below to get your free copy.Get This Free Report This page (NASDAQ:NYMX) was last updated on 7/15/2025 by MarketBeat.com Staff From Our PartnersINVESTOR ALERT: Tiny “$3 AI Wonder Stock” on the Verge of Blasting OffRight now, we’re witnessing a monumental shift in the world.Traders Agency | SponsoredMarket Panic: Trump Just Dropped a Bomb on Your Stockstock Market Panic: Trump Just Dropped a Bomb on Your Stocks The market is in freefall—and Trump's new tarif...American Alternative | SponsoredThis Signal Only Flashes Once Every 4 Years – And It Just TriggeredThis same signal has appeared twice before in the past 8 years — both times, it kicked off major moves in cryp...Crypto Swap Profits | SponsoredPresidential Bombshell: $150T Resource to Be Released as soon as this Summer?Something extraordinary is happening in Washington. For the first time in over a century, a sitting Preside...Paradigm Press | Sponsored[No Brainer Gold Play]: “Show me a better investment.”A Historic Gold Announcement Is About to Rock Wall Street? For months, sharp-eyed analysts have watched the...Golden Portfolio | SponsoredGoogle did what!?!?A new technology has sparked a modern-day gold rush in Silicon Valley. OpenAI’s Sam Altman invested $375M. Bil...Stansberry Research | SponsoredBanks aren’t ready for this altcoin—are you?Our expert analysts have identified a $100 billion gap in the crypto market. Only one project is perfectly ...Crypto 101 Media | Sponsored3..2..1.. AI 2.0 ignition (don’t sleep on this)I just put together an urgent new presentation that you need to see right away. In short: I believe we are...Timothy Sykes | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Nymox Pharmaceutical Co. Please log in to your account or sign up in order to add this asset to your watchlist. Share Nymox Pharmaceutical With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
